Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this Phase II/III study is to demonstrate that Kamada-API, a new API
concentrate manufactured by Kamada Ltd., is comparable to a currently marketed API product.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Kamada, Ltd.
Treatments:
Alpha 1-Antitrypsin Protease Inhibitors Protein C Inhibitor